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Introduction

Results

Phosphorylation of polymorphonuclear leukocyte (PMN) NADPH oxidase by
protein kinase C (PKC) is essential to generate superoxide (SO) release. Inhibition
of leukocyte SO release attenuates inflammation mediated vascular tissue injury
(e.g. myocardial ischemia/reperfusion (MI/R)). There are 11 isoforms of PKC
and the role of PKC isoforms that mediate this response has not been fully
elucidated. PKC beta II (PKC βII), a classical isoform that is activated by calcium
and diacylglycerol (DAG), following PMN chemotactic receptor stimulation with
fMLP peptide (Fig.1) (1). Activated PKC βII will activate NADPH oxidase and
stimulate SO release. Selective PKC βII peptide inhibitor has been developed
based on its binding sites to receptor for C kinase (RACK) domain (Fig 2) (2).
Myristoylation of peptides is known to be an effective strategy to enable simple
diffusion through cell membranes to affect PKC function (3, 4).
Myristoylated (Myr) PKC βII peptide inhibitor is known to inhibit PMN SO
release at doses that correlated with restoration of post-reperfused cardiac function
following global MI(20min)/R(45min) in leukocyte mediated cardiac MI/R
dysfunction (1,5) and more recently in prolonged MI(30min)/R(90min) in
isolated rat hearts (See Poster # P 204). However, a full dose-response curve
with Myr-PKC βII peptide inhibitor (0.2-20 μM) has not been indicated
previously. The peptide attenuates PKC βII translocation to the cell membrane by
inhibiting the interaction with the RACK domain (Fig.2). Characterizing the full
dose-response effects is essential in identifying putative mechanisms responsible
for attenuating vascular and tissue injury following I/R.

Figure 3. The time course response of fMLP (1μM)-induced SO release. Myr-PKC βII peptide inhibitor (0.5-20
μM) dose dependently inhibited SO release from untreated controls (*p<0.05) 21-26 ±12% (0.5 μM; 30-120 sec),
43-46 ±19% (1 μM; 30-120 sec), 58-69 ±9% (2 μM; 30-120 sec), 71-75 ±12% (5-20 μM; 30-120 sec). PKC βII
peptide inhibitor high dose groups (5-20 µM) were significantly different from the low dose group (0.2 μM)
(# p<0.05) from 30-120 sec.

Figure 2. Illustration of PKC βII peptide inhibitor. The Ca2+ binding domain for PKC βII peptide
inhibitor (i.e., C2-4 region) is unique for PKC βII translocation to the cell membrane when
activated (Adapted from 2) (top). PKC II peptide inhibitor mechanism of action (Adapted from
5) (bottom) is to inhibit PKC II translocation to leukocyte substrates such as NADPH oxidase
(Adapted from Csukai and Mochly-Rosen ).
.

Hypothesis
We hypothesized that Myr-PKC βII peptide inhibitor (0.2-20 μM) would dosedependently attenuate fMLP induced PMN SO release. We further predict that 5
to 20 μM doses would exert significant attenuation of fMLP induced PMN SO
release compared to non-drug or low drug treated (0.2 and 0.5 μM ) PMNs and these
effects would not be associated with a decrease in cell viability.

Figure 4. fMLP (1μM)-induced peak response (120 sec) SO release in PMNs. Myr-PKC βII peptide inhibitor dose
dependently (0.5-20 μM) attenuated SO release compared to untreated controls (*p<0.05; **p<0.01) by 26 ±12%
(0.5 µM), 43 ±19% (1 µM), and 69-75 ±12% (2-20 µM). PKC βII peptide inhibitor high dose groups (5-20 µM)
were significantly different from the low dose group (0.2 μM) (# p<0.05).

Methods
Isolation of PMNs
Male Sprague-Dawley rats (350–400 g, Charles River), used as PMN donors, were
anesthetized with 2.5 % isoflurane and given a 16 ml intraperitoneal injection of
0.5% glycogen (Sigma Chemical) dissolved in PBS. Rats were reanesthetized with
isoflurane 16–18 h later, and the PMNs were harvested by peritoneal lavage in 30 ml
of 0.9% NaCl, as previously described (2,3). The peritoneal lavage fluid was
centrifuged at 200 g for 10 min at 4°C. The PMNs were then washed in 20 ml PBS
and centrifuged at 200 g for 10 min at 4°C. Thereafter, the PMNs were
resuspended in 2.5 ml PBS and density was calculated. The PMNs preparation were
>90% pure and >95% viable according to microscopic analysis and exclusion of
0.3% trypan blue, respectively. Cell viability among all study groups was
determined by 0.3% trypan blue exclusion.
Measurement of SO Release From Rat PMNs
The SO release from PMNs was measured spectrophotometrically (model 260
Gilford, Nova Biotech; El Cajon, CA) by the reduction of ferricytochrome c (1,3).
The PMNs (5 x106) were resuspended in 450 μl PBS and incubated with
ferricytochrome c (100 µM, Sigma Chemical) in a total volume of 900 μl PBS in the
presence or absence of myr PKC βII inhibitor (0.2 to 20 μM; N-myr-SLNPEWNET ,
1300 g/mol) for 15 min at 37°C in spectrophotometric cells. The PMNs were
stimulated with 1 μM fMLP (MW= 434 g/mol) (Calbiochem) in a final reaction
volume of 1.0 ml. Absorbance at 550 nm was measured every 30 sec for up to
Figure 1. Schematic representation of PKC activation generating SO release in PMN. PMN
120sec for fMLP and the change in absorbance (SO release) from PMNs was
chemotactic G-protein receptors are activated by fMLP. The G-protein subunits q and βγ
determined relative to time 0.
disassociate after stimulation and activate phospholipase C beta (PLCβ) to produce inositol 1,4,5
Statistical Analysis
trisphosphate (Ins(1,4,5)P2) plus DAG respectively from phospholipids phosphatidylinositol 4,5
bisphosphate (PtdIns(4,5)P2). Ins(1,4,5)P2 stimulates Ca2+ release from the endoplasmic reticulum All data in the text and figures are presented as means ± S.E.M. The data were
analyzed by analysis of variance using post hoc analysis with the Fisher’s PLSD
(ER). Ca2+ and DAG directly activate PKC βII . Activated PKC βII phosphorylates NADPH
test. Probability values of <0.05 are considered to be statistically significant.
oxidase to release SO (Adapted from Young et al.).

Figure 5. . The effects of Myr-PKC βII peptide inhibitor (0.2-20 µM) on cell viability in fMLP (1 μM)-induced SO
release in PMNs. Cell viability ranged between 94-96% ± 1 and was not different amongst study groups,
suggesting that the inhibition of leukocyte SO release was not related to cell death

Conclusions
Myr-PKC βII peptide inhibitor dose-dependently inhibited fMLP-induced SO
release by about 70%; suggesting that activation of NADPH oxidase via PKC βII
is the dominant pathway following stimulation of the leukocyte chemotactic
receptor. This study suggests that PKC βII peptide inhibitor maybe antiinflammatory agent that can be used in vascular complications associated with
I/R.
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